Cargando…

Cannabinoids for the treatment of refractory neuropathic pruritus in amyotrophic lateral sclerosis: A case report

BACKGROUND: Neuropathic symptoms have a wide variety of manifestations, ranging from pain to pruritus. Neuropathic pruritus is a type of chronic pruritus related to damaged small fibers. Cannabinoids have evidence to manage neuropathic symptoms. We present a case of refractory neuropathic pruritus t...

Descripción completa

Detalles Bibliográficos
Autores principales: Lou, Kelvin, Murphy, Shane, Talbot, Clair
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8796147/
https://www.ncbi.nlm.nih.gov/pubmed/34510973
http://dx.doi.org/10.1177/02692163211045314
_version_ 1784641240436834304
author Lou, Kelvin
Murphy, Shane
Talbot, Clair
author_facet Lou, Kelvin
Murphy, Shane
Talbot, Clair
author_sort Lou, Kelvin
collection PubMed
description BACKGROUND: Neuropathic symptoms have a wide variety of manifestations, ranging from pain to pruritus. Neuropathic pruritus is a type of chronic pruritus related to damaged small fibers. Cannabinoids have evidence to manage neuropathic symptoms. We present a case of refractory neuropathic pruritus that was successfully managed with the use of oral cannabinoids. CASE PRESENTATION: A 60-year-old male with amyotrophic lateral sclerosis with ongoing pruritus despite the use of standard neuropathic therapies. POSSIBLE COURSE OF ACTION: Sodium channel and N-methyl-D-aspartate receptor antagonists have evidence for neuropathic symptoms but can cause significant gastrointestinal side effects. Prescription cannabinoids such as nabiximol can be cost prohibitive to use in practice. Synthetic tetrahydrocannabinol products are dose limited by psychoactive side effects. FORMULATION OF A PLAN: A balanced oral cannabinoid from a licensed producer was preferred as it has evidence for neuropathic symptoms and is generally well tolerated. OUTCOME: The patient showed improvement to his pruritus score from 7/10 to 3/10. There was initial increased sedation but tolerance developed quickly. LESSONS LEARNED FROM CASE: Cannabinoids are possibly safe and effective in management of neuropathic pruritus. VIEW ON RESEARCH PROBLEMS: Additional research is needed to establish efficacy and safety.
format Online
Article
Text
id pubmed-8796147
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-87961472022-01-29 Cannabinoids for the treatment of refractory neuropathic pruritus in amyotrophic lateral sclerosis: A case report Lou, Kelvin Murphy, Shane Talbot, Clair Palliat Med Case Report BACKGROUND: Neuropathic symptoms have a wide variety of manifestations, ranging from pain to pruritus. Neuropathic pruritus is a type of chronic pruritus related to damaged small fibers. Cannabinoids have evidence to manage neuropathic symptoms. We present a case of refractory neuropathic pruritus that was successfully managed with the use of oral cannabinoids. CASE PRESENTATION: A 60-year-old male with amyotrophic lateral sclerosis with ongoing pruritus despite the use of standard neuropathic therapies. POSSIBLE COURSE OF ACTION: Sodium channel and N-methyl-D-aspartate receptor antagonists have evidence for neuropathic symptoms but can cause significant gastrointestinal side effects. Prescription cannabinoids such as nabiximol can be cost prohibitive to use in practice. Synthetic tetrahydrocannabinol products are dose limited by psychoactive side effects. FORMULATION OF A PLAN: A balanced oral cannabinoid from a licensed producer was preferred as it has evidence for neuropathic symptoms and is generally well tolerated. OUTCOME: The patient showed improvement to his pruritus score from 7/10 to 3/10. There was initial increased sedation but tolerance developed quickly. LESSONS LEARNED FROM CASE: Cannabinoids are possibly safe and effective in management of neuropathic pruritus. VIEW ON RESEARCH PROBLEMS: Additional research is needed to establish efficacy and safety. SAGE Publications 2021-09-11 2022-01 /pmc/articles/PMC8796147/ /pubmed/34510973 http://dx.doi.org/10.1177/02692163211045314 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/This article is distributed under the terms of the Creative Commons Attribution 4.0 License (https://creativecommons.org/licenses/by/4.0/) which permits any use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Case Report
Lou, Kelvin
Murphy, Shane
Talbot, Clair
Cannabinoids for the treatment of refractory neuropathic pruritus in amyotrophic lateral sclerosis: A case report
title Cannabinoids for the treatment of refractory neuropathic pruritus in amyotrophic lateral sclerosis: A case report
title_full Cannabinoids for the treatment of refractory neuropathic pruritus in amyotrophic lateral sclerosis: A case report
title_fullStr Cannabinoids for the treatment of refractory neuropathic pruritus in amyotrophic lateral sclerosis: A case report
title_full_unstemmed Cannabinoids for the treatment of refractory neuropathic pruritus in amyotrophic lateral sclerosis: A case report
title_short Cannabinoids for the treatment of refractory neuropathic pruritus in amyotrophic lateral sclerosis: A case report
title_sort cannabinoids for the treatment of refractory neuropathic pruritus in amyotrophic lateral sclerosis: a case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8796147/
https://www.ncbi.nlm.nih.gov/pubmed/34510973
http://dx.doi.org/10.1177/02692163211045314
work_keys_str_mv AT loukelvin cannabinoidsforthetreatmentofrefractoryneuropathicpruritusinamyotrophiclateralsclerosisacasereport
AT murphyshane cannabinoidsforthetreatmentofrefractoryneuropathicpruritusinamyotrophiclateralsclerosisacasereport
AT talbotclair cannabinoidsforthetreatmentofrefractoryneuropathicpruritusinamyotrophiclateralsclerosisacasereport